CAPTAIN-1ST

NCT03707509 📎

Regimen

Experimental
Camrelizumab 200 mg IV q3w + gemcitabine/cisplatin (GP) ×4–6 cycles, then camrelizumab maintenance
Control
Placebo IV q3w + gemcitabine/cisplatin (GP) ×4–6 cycles, then placebo maintenance

Population

Treatment-naive recurrent or metastatic NPC; ECOG PS 0–1; enrolled at 29 sites in China

Key finding

Camrelizumab (Hengrui 恒瑞 domestic Chinese anti-PD-1) plus GP significantly improved PFS over GP alone in treatment-naive RM NPC. The HR of 0.54 was consistent with the parallel JUPITER-02 trial (HR 0.52), confirming that the PD-1 + GP strategy is robust across different domestic Chinese antibodies. This is the second trial of the Chinese phase 3 triad.

Source: PMID 34174189

Timeline

    Guideline citations

    • NCCN NPC (p.43)